Turkey's President Tayyip Erdogan has said ride hailing app Uber is finished in Turkey, following pressure from Istanbul taxi drivers who said it was providing an illegal service and called for it to be banned.

About 17,400 taxis operate in Istanbul, home to about a fifth of Turkey's population of 81 million people, and since Uber entered the country in 2014 tensions have risen sharply.

Erdogan's statement came after new regulations were announced in recent weeks tightening transport licensing requirements, making it more difficult for drivers to register with Uber and threatening a two-year ban for violations.

"This thing called Uber emerged. That business is finished. That does not exist anymore," he said in a speech in Istanbul late on Friday.

"We have our taxi system. Where does this (Uber) come from? It is used in Europe, I do not care about that. We will decide by ourselves," added Erdogan, who is running for re-election in three weeks.

Uber had no immediate response to his comment. After the transport licensing changes were announced it said it wanted to work with all sides to improve transport and to be "a true partner to Turkey for the long term".

Uber said that about 2,000 yellow cab drivers use its app to find customers, while another 5,000 work for UberXL, using large vans to transport groups to parties, or take people with bulky luggage to Istanbul's airports.

It declined to reveal the number of Uber users in Turkey, where it operates in Istanbul, and in the resort towns of Bodrum and Cesme in the summer months.

Earlier this year, Istanbul's taxi drivers took Uber to court accusing it of hindering their business and operating illegally.

Several reports said that Uber vehicles, drivers and customers were either mistreated, threatened or faced violence by yellow taxi drivers.

Erdogan's statement came following pressure from Istanbul's taxi drivers who said Uber was providing an illegal service and called for it to be banned

Turkey's President Tayyip Erdogan has said ride hailing app Uber is finished in Turkey, following pressure from Istanbul taxi drivers who said it was providing an illegal service and called for it to be banned. About 17,400 taxis operate in Istanbul, home to about a fifth of Turkey's population of 81 million people, and since Uber entered the country in 2014 tensions have risen sharply. Erdogan's statement came after new regulations were announced in recent weeks tightening transport licensing requirements, making it more difficult for drivers to register with Uber and threatening a two-year ban for violations. "This thing called Uber emerged. That business is finished. That does not exist anymore," he said in a speech in Istanbul late on Friday. "We have our taxi system. Where does this (Uber) come from? It is used in Europe, I do not care about that. We will decide by ourselves," added Erdogan, who is running for re-election in three weeks. Uber had no immediate response to his comment. After the transport licensing changes were announced it said it wanted to work with all sides to improve transport and to be "a true partner to Turkey for the long term". Uber said that about 2,000 yellow cab drivers use its app to find customers, while another 5,000 work for UberXL, using large vans to transport groups to parties, or take people with bulky luggage to Istanbul's airports. It declined to reveal the number of Uber users in Turkey, where it operates in Istanbul, and in the resort towns of Bodrum and Cesme in the summer months. Earlier this year, Istanbul's taxi drivers took Uber to court accusing it of hindering their business and operating illegally. Several reports said that Uber vehicles, drivers and customers were either mistreated, threatened or faced violence by yellow taxi drivers.

Uber's 'business is finished' in Turkey, says Erdogan

Mice given a single shot of one of two experimental Zika vaccines were completely protected when exposed to the virus one to two months later, a promising sign that similar vaccines under development for humans will protect against Zika, US researchers said on Tuesday. 
 
&ldquo;This is an encouraging first step in Zika vaccine design and pre-clinical testing. This new mouse model should be useful for comparative assessments of the large range of vaccine candidates now being designed,&quot; said Professor Adrian Hill, director of Oxford University&#39;s Jenner Institute, which did not conduct the mouse study but is also developing Zika vaccines. 
 
Separately, US scientists said they have developed a model of the Zika virus in monkeys, a close proxy for human disease. 
 
The studies advance efforts in fighting the mosquito-borne Zika virus, which has swept through the Americas and Caribbean since last fall, and has been linked to thousands of cases of microcephaly, a rare birth defect, in Brazil, as well as to neurological disorders. On February 1, the World Health Organization declared Zika a global health emergency. 
 
&ldquo;With diseases spread by biting insects, such as Zika, standard quarantine measures are useless, so stopping an outbreak in its tracks requires a vaccine-led approach,&quot; said Dr Derek Gatherer, a lecturer in the division of biomedical and life sciences at Britain&#39;s Lancaster University. 
 
In the mouse study, published in the journal Nature, a team led by Dr Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School, tested two different vaccine candidates in a strain of mice that develops Zika symptoms. 
 
One candidate, a DNA vaccine, was developed by Barouch and colleagues. It contains bits of genetic material from a Zika virus strain from Brazil. 
 
The other was made from a purified but inactivated version of the Zika virus from Puerto Rico. That vaccine was developed by researchers at Walter Reed Army Institute of Research in Silver Spring, Maryland. 
 
Mice given either type of vaccine were 100 per cent protected from Zika after a single shot. Unvaccinated mice that were exposed to the virus all developed symptoms of Zika. 
 
Both types of vaccines - DNA and inactivated virus vaccines - have been successfully developed to prevent infection from viruses related to Zika, including West Nile and dengue. 
 
The team also showed that antibodies taken from immunized mice could be used to protect other, unvaccinated mice, offering proof that the antibodies produced by the vaccines were specific to Zika. 
 
&quot;We need to be cautious about extrapolating data from a mouse model into humans,&quot; Barouch said. But the fact that the vaccines protected mice and that their antibodies protected other mice from Zika was grounds for optimism over the development of a Zika vaccine, he said. 
 
At least 15 companies and academic groups are racing to develop Zika vaccines, according to the WHO. US vaccine maker Inovio Pharmaceuticals last week got US Food and Drug Administration approval to begin testing its Zika DNA vaccine in humans. 
 
Oxford University&#39;s Hill stressed that there are still years of testing needed before a finished vaccine will be available for humans. 
 
MONKEY INFECTION 
 
In another advance, researchers at the University of Wisconsin reported on Tuesday that they have successfully infected rhesus macaques with an Asian strain of the Zika virus that is currently circulating in the Americas. The study, published in the journal Nature Communications, shows that monkeys - which have immune responses similar to humans - can be used to study Zika. 
 
In the study, David O&#39;Connor and colleagues inoculated eight rhesus macaques - including two pregnant monkeys - with a strain of Zika virus currently circulating in the Americas. 
 
All eight animals were infected. Tests showed viral particles in their blood, saliva, urine and spinal fluid. All animals stayed infected for at least 21 days, and some remained infected for at least 57 days. 
 
A second exposure to Zika 10 weeks after the first did not make the animals sick, suggesting that antibodies developed by the monkeys protected them against a second case of Zika. This is a promising sign that humans may similarly be able to develop protective antibodies against the virus. 
 
The scientists are still working to understand whether the pregnant monkeys will pass the infection along to their fetuses, and whether infected monkeys can transmit the virus sexually, as has been seen in infected humans. 
 
US health officials have concluded that Zika infections in pregnant women can cause microcephaly, a birth defect marked by small head size that can lead to severe developmental problems in babies. The WHO has said there is strong scientific consensus that Zika can also cause Guillain-Barre, a rare neurological syndrome that causes temporary paralysis in adults. 
 
(Reuters)

Encouraging tests have been conducted on both mice and monkeys, but it'll be years before humans have a finished Zika vaccine

Mice given a single shot of one of two experimental Zika vaccines were completely protected when exposed to the virus one to two months later, a promising sign that similar vaccines under development for humans will protect against Zika, US researchers said on Tuesday. “This is an encouraging first step in Zika vaccine design and pre-clinical testing. This new mouse model should be useful for comparative assessments of the large range of vaccine candidates now being designed," said Professor Adrian Hill, director of Oxford University's Jenner Institute, which did not conduct the mouse study but is also developing Zika vaccines. Separately, US scientists said they have developed a model of the Zika virus in monkeys, a close proxy for human disease. The studies advance efforts in fighting the mosquito-borne Zika virus, which has swept through the Americas and Caribbean since last fall, and has been linked to thousands of cases of microcephaly, a rare birth defect, in Brazil, as well as to neurological disorders. On February 1, the World Health Organization declared Zika a global health emergency. “With diseases spread by biting insects, such as Zika, standard quarantine measures are useless, so stopping an outbreak in its tracks requires a vaccine-led approach," said Dr Derek Gatherer, a lecturer in the division of biomedical and life sciences at Britain's Lancaster University. In the mouse study, published in the journal Nature, a team led by Dr Dan Barouch of Beth Israel Deaconess Medical Center and Harvard Medical School, tested two different vaccine candidates in a strain of mice that develops Zika symptoms. One candidate, a DNA vaccine, was developed by Barouch and colleagues. It contains bits of genetic material from a Zika virus strain from Brazil. The other was made from a purified but inactivated version of the Zika virus from Puerto Rico. That vaccine was developed by researchers at Walter Reed Army Institute of Research in Silver Spring, Maryland. Mice given either type of vaccine were 100 per cent protected from Zika after a single shot. Unvaccinated mice that were exposed to the virus all developed symptoms of Zika. Both types of vaccines - DNA and inactivated virus vaccines - have been successfully developed to prevent infection from viruses related to Zika, including West Nile and dengue. The team also showed that antibodies taken from immunized mice could be used to protect other, unvaccinated mice, offering proof that the antibodies produced by the vaccines were specific to Zika. "We need to be cautious about extrapolating data from a mouse model into humans," Barouch said. But the fact that the vaccines protected mice and that their antibodies protected other mice from Zika was grounds for optimism over the development of a Zika vaccine, he said. At least 15 companies and academic groups are racing to develop Zika vaccines, according to the WHO. US vaccine maker Inovio Pharmaceuticals last week got US Food and Drug Administration approval to begin testing its Zika DNA vaccine in humans. Oxford University's Hill stressed that there are still years of testing needed before a finished vaccine will be available for humans. MONKEY INFECTION In another advance, researchers at the University of Wisconsin reported on Tuesday that they have successfully infected rhesus macaques with an Asian strain of the Zika virus that is currently circulating in the Americas. The study, published in the journal Nature Communications, shows that monkeys - which have immune responses similar to humans - can be used to study Zika. In the study, David O'Connor and colleagues inoculated eight rhesus macaques - including two pregnant monkeys - with a strain of Zika virus currently circulating in the Americas. All eight animals were infected. Tests showed viral particles in their blood, saliva, urine and spinal fluid. All animals stayed infected for at least 21 days, and some remained infected for at least 57 days. A second exposure to Zika 10 weeks after the first did not make the animals sick, suggesting that antibodies developed by the monkeys protected them against a second case of Zika. This is a promising sign that humans may similarly be able to develop protective antibodies against the virus. The scientists are still working to understand whether the pregnant monkeys will pass the infection along to their fetuses, and whether infected monkeys can transmit the virus sexually, as has been seen in infected humans. US health officials have concluded that Zika infections in pregnant women can cause microcephaly, a birth defect marked by small head size that can lead to severe developmental problems in babies. The WHO has said there is strong scientific consensus that Zika can also cause Guillain-Barre, a rare neurological syndrome that causes temporary paralysis in adults. (Reuters)

Zika vaccine tests successful on mice

finished

Finished, News on Finished, stories on Finished, articles on Finished, Finished stories at Wion, Finished news, Finished latest news